24/7 Market News Snapshot 28 August, 2025 – Enveric Biosciences, Inc. Common Stock (NASDAQ:ENVB)

August 28, 2025

DENVER, Colo., 28 August, 2025 (www.247marketnews.com) – (NASDAQ:ENVB) are discussed in this article.
Enveric Biosciences, Inc. (NASDAQ:ENVB) is currently facing a challenging trading scenario as it experiences a decline of 4.48% in pre-market sessions, positioning its stock price at $1.385 compared to the previous close of $1.450. The trading session saw a volume of 1.70 million shares, indicating active market participation. The bearish trend might reflect broader market dynamics or specific developments associated with the company, prompting investors to closely monitor support levels as they navigate potential breakdown points.

Amid this market context, Enveric has also made significant strides in its drug development efforts, announcing the successful completion of 7-day Dose Range Finding (DRF) toxicology studies for its lead candidate, EB-003. This achievement marks a critical step forward in advancing to First-in-Human clinical trials aimed at treating conditions like depression and post-traumatic stress disorder (PTSD).

The DRF studies were meticulously designed to assess toxicity and pharmacokinetics following daily oral administration of EB-003 in two preclinical species. Findings established a well-defined Maximum Tolerated Dose (MTD), demonstrating oral bioavailability along with dose-dependent increases in plasma concentrations. Higher doses indicated potential central nervous system (CNS) effects, affirming EB-003’s capability to penetrate the brain and interact with relevant receptors.

Dr. Joseph Tucker, the company’s Chief Executive Officer, highlighted the significance of these findings, which are pivotal for establishing dosing strategies and preparing for subsequent regulatory submissions. EB-003 represents a groundbreaking neuroplastogen that selectively engages serotonin receptors, providing an innovative alternative with a focus on mood regulation and neuroplasticity, without the hallucinogenic effects often associated with similar therapies.

As Enveric Biosciences progresses with its development plans, the company remains resolute in its mission to meet the unmet needs in psychiatric treatment, emphasizing its commitment to delivering advanced therapeutic options for chronic neuropsychiatric disorders.

Related news for (ENVB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.